Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 5/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 5/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954005 | 0.93 | KDM4E (0.49) | KDM4EPOLA1NR2F2CYP1A2ALDH1A1 | |
| SCHEMBL27159645 | 0.89 | KDM4E (0.49) | KDM4EPOLA1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL24513581 | 0.88 | KDM4E (0.48) | KDM4EPOLA1NR2F2CYP1A2ALDH1A1 | |
| SCHEMBL26985829 | 0.87 | KDM4E (0.46) | KDM4EPOLA1NR2F2CYP1A2ALDH1A1 | |
| SCHEMBL15090394 | 0.86 | KDM4E (0.41) | KDM4EPOLA1NR2F2CYP1A2ALDH1A1 | |
| SCHEMBL24517731 | 0.86 | KDM4E (0.45) | KDM4EPOLA1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL30177246 | 0.86 | KDM4E (0.45) | KDM4EPOLA1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL29317394 | 0.84 | KDM4E (0.44) | KDM4EPOLA1CYP1A2ALDH1A1TAS1R3 | |
| SCHEMBL21636142 | 0.83 | KDM4E (0.43) | KDM4EPOLA1CYP1A2ALDH1A1TAS1R3 | |
| SCHEMBL22990581 | 0.82 | KDM4E (0.62) | KDM4EPOLA1CYP1A2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551580-A2 | CRYSTALLINE MONOMERS FOR PREPARING ANTISENSE OLIGONUCLEOTIDES AND METHODS OF THEIR PREPARATION AND USE | Eisai R&D Management Co., Ltd. (JP) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010870-A2 | CRYSTALLINE MONOMERS FOR PREPARING ANTISENSE OLIGONUCLEOTIDES AND METHODS OF THEIR PREPARATION AND USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010870-A2 | CRYSTALLINE MONOMERS FOR PREPARING ANTISENSE OLIGONUCLEOTIDES AND METHODS OF THEIR PREPARATION AND USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-01-11 | — | — | WO | disclosed |
| EP-4259798-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | Eisai R&D Management Co., Ltd. (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| WO-2022125984-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125987-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125987-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | KDM4E 4665/4885POLA1 112/4885NR2F2 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.